We propose treatment as follows: (1) PanIN, anti-CTLA-4, eventually combined with an antagonist targeting the pro-inflammatory cytokine receptor CCR1, and (2) IPMN, anti-PD-L1/PD-1. This evidence concerns the gene CCR1 and pancreatic intraductal papillary-mucinous neoplasm.